OM
ITCI

Opaleye Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Opaleye Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-406,600
Closed -$13.9M – 52
2019
Q4 		$13.9M Buy
406,600
+236,600
+139% +$2.84M 2.74% 15
2019
Q3 		$1.27M Buy
+170,000
New +$1.63M 0.46% 43

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's ITCI Position: Q1 2020 in Review

Opaleye Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 406,600 shares — an estimated $13.9M sold.

Opaleye Management first reported a position in ITCI in Q3 2019 and held it in 2 quarters. The position peaked at $13.9M in Q4 2019. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Opaleye Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • Opaleye Management sold 406,600 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $13.9M.
  • Opaleye Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 2 quarters.
  • Opaleye Management's Intra-Cellular Therapies Inc. position peaked at $13.9M in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.